Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Evoke Pharma ( (EVOK) ) just unveiled an announcement.
Evoke Pharma, Inc. has appointed Benjamin Smeal as a Class II director with a term expiring at the 2027 annual meeting. Smeal, a seasoned investor with a background in public equities and hedge funds, will serve on key committees, bringing valuable expertise to the board. As part of the non-employee director compensation program, he receives stock options and cash compensation, enhancing the company’s strategic direction and governance.
Learn more about EVOK stock on TipRanks’ Stock Analysis page.
